Why carry out the study?

Latanoprostene bunod ophthalmic solution (LBN) 0.024% is a nitric oxide-donating prostaglandin analog demonstrated in clinical trials to lower intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension.

This retrospective medical chart review evaluated the IOP-lowering efficacy of LBN in patients newly diagnosed with OAG known to be treatment-naïve, a population not specifically evaluated in clinical trials.

What was learned from the study?

In the overall data set (n = 65 patients), LBN treatment resulted in mean IOP lowering of 31% in treatment-naïve OAG patients with a mean baseline IOP of 21.7 mmHg; percent IOP lowering was 41% and 22% in the subsets of patients with baseline IOP > 21 mmHg and ≤ 21 mmHg, respectively.

While prospective studies are warranted to confirm these findings, these data support the use of LBN in OAG patients naïve to therapy.